DK0568575T4 - Test og model for Alzheimers sygdom - Google Patents

Test og model for Alzheimers sygdom

Info

Publication number: DK0568575T4
Authority: DK; Denmark
Prior art keywords: alzheimer; amino acid; disease; model; test
Prior art date: 1991-01-21

Application number

DK92903304.1T

Other languages

English (en)

Other versions

DK0568575T3 (da

Inventor

Michael John Owen

John Anthony Hardy

Marie-Christine Chartier-Harlin

Alison Mary Goate

Michael John Mullan

Original Assignee

Elan Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-01-21

Filing date

1992-01-21

Publication date

2010-12-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0568575(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-01-21 Priority claimed from GB919101307A external-priority patent/GB9101307D0/en

1991-08-28 Priority claimed from GB919118445A external-priority patent/GB9118445D0/en

1992-01-21 Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc

2005-05-23 Publication of DK0568575T3 publication Critical patent/DK0568575T3/da

2010-12-20 Application granted granted Critical

2010-12-20 Publication of DK0568575T4 publication Critical patent/DK0568575T4/da

Links

208000024827 Alzheimer disease Diseases 0.000 title abstract 3
101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 2
101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 2
102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 2
125000003275 alpha amino acid group Chemical group 0.000 abstract 2
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 2
208000034826 Genetic Predisposition to Disease Diseases 0.000 abstract 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
102000001708 Protein Isoforms Human genes 0.000 abstract 1
108010029485 Protein Isoforms Proteins 0.000 abstract 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
125000000539 amino acid group Chemical group 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000006467 substitution reaction Methods 0.000 abstract 1
239000004474 valine Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Environmental Sciences (AREA)
Neurology (AREA)
Toxicology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Animal Behavior & Ethology (AREA)
Pathology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Plant Pathology (AREA)
Biodiversity & Conservation Biology (AREA)
Animal Husbandry (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)

DK92903304.1T 1991-01-21 1992-01-21 Test og model for Alzheimers sygdom DK0568575T4 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB919101307A GB9101307D0 (en)	1991-01-21	1991-01-21	Test for alzheimers disease
GB919118445A GB9118445D0 (en)	1991-08-28	1991-08-28	Test for alzheimer's disease
PCT/GB1992/000123 WO1992013069A1 (en)	1991-01-21	1992-01-21	Test and model for alzheimer's disease

Publications (2)

Publication Number	Publication Date
DK0568575T3 DK0568575T3 (da)	2005-05-23
DK0568575T4 true DK0568575T4 (da)	2010-12-20

Family

ID=26298303

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK99109196T DK0971033T3 (da)	1991-01-21	1992-01-21	Test og model til Alzheimers sygdom
DK92903304.1T DK0568575T4 (da)	1991-01-21	1992-01-21	Test og model for Alzheimers sygdom

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK99109196T DK0971033T3 (da)	1991-01-21	1992-01-21	Test og model til Alzheimers sygdom

Country Status (10)

Country	Link
US (3)	US5877015A (da)
EP (2)	EP0971033B1 (da)
JP (3)	JP3510244B2 (da)
AT (2)	ATE447016T1 (da)
AU (1)	AU652997B2 (da)
CA (2)	CA2372251A1 (da)
DE (3)	DE69233774D1 (da)
DK (2)	DK0971033T3 (da)
ES (2)	ES2236682T5 (da)
WO (1)	WO1992013069A1 (da)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2236682T5 (es)	1991-01-21	2011-03-31	Elan Pharmaceuticals, Inc.	Ensayo y modelo para la enfermedad de alzheimer.
JP3277211B2 (ja) *	1991-11-12	2002-04-22	プラナ・バイオテクノロジー・リミテッド	アルツハイマー病の試験方法と治療方法
WO1993013114A1 (en) *	1991-12-24	1993-07-08	Isis Pharmaceuticals, Inc.	COMPOSITIONS AND METHODS FOR MODULATING β-AMYLOID
AU671093B2 (en) *	1992-01-07	1996-08-15	Elan Pharmaceuticals, Inc.	Transgenic animal models for alzheimer's disease
US5604131A (en) *	1992-01-07	1997-02-18	Athena Neurosciences, Inc.	cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regions
US5455169A (en) *	1992-06-04	1995-10-03	Alzheimer's Institute Of America, Inc.	Nucleic acids for diagnosing and modeling Alzheimer's disease
US6610493B1 (en)	1993-06-17	2003-08-26	Brigham And Women's Hospital	Screening compounds for the ability to alter the production of amyloid-β peptide
US6328971B1 (en) *	1993-01-22	2001-12-11	Ludwig Institute For Cancer Research	MAGE-1 derived nona peptides, and compositions thereof
AU702293B2 (en) *	1993-10-27	1999-02-18	Athena Neurosciences, Inc.	Transgenic animals harboring APP allele having Swedish mutation
JPH07132033A (ja) *	1993-11-12	1995-05-23	Hoechst Japan Ltd	アルツハイマー病モデルトランスジェニック動物
DE69533583T2 (de)	1994-01-27	2005-10-06	Regents of the University of Minnesota, Southeast, Minneapolis	Nicht humane, transgenische säugetiere mit sich entwickelnder neurologischer krankheit
US5877399A (en)	1994-01-27	1999-03-02	Johns Hopkins University	Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
WO1996006927A1 (en) *	1994-09-01	1996-03-07	Merck & Co., Inc.	Transgenic animal expressing a familial form of human amyloid precursor protein
US6187992B1 (en)	1994-12-05	2001-02-13	Merck & Co., Inc.	Transgenic mouse having a disrupted amyloid precursor protein gene
US5674681A (en) *	1994-12-06	1997-10-07	Rothenberg; Barry E.	Methods to identify hemochromatosis
JP2001517065A (ja) *	1995-06-07	2001-10-02	アセナニューロサイエンシーズ，インコーポレイテッド	トランスジェニック動物モデルを用いてアルツハイマー病治療薬を同定する方法
US6717031B2 (en)	1995-06-07	2004-04-06	Kate Dora Games	Method for selecting a transgenic mouse model of alzheimer's disease
AUPN649395A0 (en) *	1995-11-10	1995-12-07	Ramsay Health Care Pty Ltd	A method for diagnosing alzheimer's disease
US7129061B1 (en) *	1996-08-07	2006-10-31	Biogen Idec Ma Inc.	Tumor necrosis factor related ligand
CA2183901A1 (en) *	1996-08-22	1998-02-23	Johanna E. Bergmann	Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
US6933331B2 (en) *	1998-05-22	2005-08-23	Nanoproducts Corporation	Nanotechnology for drug delivery, contrast agents and biomedical implants
US5898094A (en) *	1996-10-21	1999-04-27	University Of South Florida	Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
ES2128265B1 (es) *	1997-06-04	2000-03-01	Euroespes S A	Kit genetico para la caracterizacion molecular de la enfermedad de alzheimer.
FR2770217B1 (fr) *	1997-10-24	2001-12-07	Rhone Poulenc Rorer Sa	Peptides capables d'inhiber l'interaction entre les presenilines et le precurseur du peptide b-amyloide et/ou le peptide b-amyloide
CN100429230C (zh) *	1997-10-24	2008-10-29	阿文蒂斯药物股份有限公司	能抑制早老素和β-淀粉样肽或其前体间相互作用的肽
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US6923964B1 (en)	1997-12-02	2005-08-02	Neuralab Limited	Active immunization of AScr for prion disorders
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US6710226B1 (en)	1997-12-02	2004-03-23	Neuralab Limited	Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
PL205294B1 (pl)	1998-09-24	2010-03-31	Upjohn Co	Izolowany lub oczyszczony polipeptyd, oczyszczony lub izolowany polinukleotyd, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania polipeptydu, sposoby identyfikowania czynnika obniżającego, modulującego lub hamującego aktywność, zastosowanie takiego czynnika, izolowany kwas nukleinowy, obejmujący go wektor i ich zastosowanie, sposoby zmniejszania komórkowego wytwarzania beta amyloidu i zastosowanie antysensownego reagenta
US6844148B1 (en) *	1998-09-24	2005-01-18	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US20040234976A1 (en) *	1998-09-24	2004-11-25	Gurney Mark E.	Alzheimer's disease secretase, app substrates therefor, and uses therefor
US6699671B1 (en)	1998-09-24	2004-03-02	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US7115410B1 (en) *	1999-02-10	2006-10-03	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
US7456007B1 (en)	1998-12-31	2008-11-25	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
GB2364059B (en)	1999-02-10	2004-01-14	Elan Pharm Inc	Beta-Secretase enzyme compositions and methods
US6355425B1 (en) *	1999-03-26	2002-03-12	Billups-Rothenberg, Inc.	Mutations associated with iron disorders
US7056661B2 (en) *	1999-05-19	2006-06-06	Cornell Research Foundation, Inc.	Method for sequencing nucleic acid molecules
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
US20090162883A1 (en) *	1999-09-23	2009-06-25	Pharmacia & Upjohn Company	Alzheimer's Disease Secretase, APP Substrates Thereof, and Uses Thereof
US7514408B1 (en)	1999-12-02	2009-04-07	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
US6310048B1 (en)	1999-12-09	2001-10-30	St. Louis University	Antisense modulation of amyloid beta protein expression
WO2001047944A2 (en) *	1999-12-28	2001-07-05	Curagen Corporation	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
DE60124080T2 (de) *	2000-03-23	2007-03-01	Elan Pharmaceuticals, Inc., San Francisco	Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6992081B2 (en)	2000-03-23	2006-01-31	Elan Pharmaceuticals, Inc.	Compounds to treat Alzheimer's disease
EP1666452A2 (en)	2000-06-30	2006-06-07	Elan Pharmaceuticals, Inc.	Compounds to treat Alzheimer's disease
PE20020276A1 (es)	2000-06-30	2002-04-06	Elan Pharm Inc	COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) *	2000-06-30	2005-01-25	Pharmacia & Upjohn Company	Compounds to treat alzheimer's disease
US20030096864A1 (en) *	2000-06-30	2003-05-22	Fang Lawrence Y.	Compounds to treat alzheimer's disease
JP2004502664A (ja) *	2000-06-30	2004-01-29	イーラン　ファーマスーティカルズ、インコーポレイテッド	アルツハイマー病処置用化合物
AU2001269127A1 (en) *	2000-07-06	2002-01-14	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	A novel app mutation associated with an unusual alzheimer's disease pathology
PE20020574A1 (es)	2000-12-06	2002-07-02	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
MXPA03011046A (es) *	2001-06-01	2004-06-25	Elan Pharm Inc	Hidroxialquilaminas.
US6906104B2 (en)	2001-06-13	2005-06-14	Pharmacia & Upjohn Company	Aminediols for the treatment of Alzheimer's disease
BR0210721A (pt) *	2001-06-27	2004-07-20	Elan Pharm Inc	Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição
US20070213407A1 (en) *	2001-06-29	2007-09-13	Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc	Compounds to treat Alzheimer's disease
BR0211121A (pt) *	2001-07-10	2004-10-26	Elan Pharm Inc	Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
MXPA04000338A (es) *	2001-07-10	2004-07-23	Upjohn Co	Diamindioles para tratamiento de enfermedad de alzheimer.
US7297553B2 (en) *	2002-05-28	2007-11-20	Nanosphere, Inc.	Method for attachment of silylated molecules to glass surfaces
EP1432674A2 (en)	2001-10-04	2004-06-30	Elan Pharmaceuticals, Inc.	Hydroxypropylamines
AU2002359376B2 (en) *	2001-11-08	2008-01-10	Elan Pharmaceuticals, Inc.	N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
BR0214297A (pt) *	2001-11-19	2004-11-09	Upjohn Co	Métodos de tratar ou prevenir mal de alzheimer em um indivìduo e uma doença distinguida por depósitos de beta-amilóide sobre ou no cérebro, de tratar mal de alzheimer um indivìduo que apresenta, ou de prevenir que um indivìduo adquira, uma doença ou condição, de inibir atividade de beta-secretase, clivagem de um isótipo de protéina precursora amilóide e produção de peptìdeo beta amilóide e de placa beta-amilóide em um animal e de produzir um complexo de beta-secretase e uso de um composto, e, composição
US20040016008A1 (en) *	2002-01-07	2004-01-22	Brimijoin William Stephen	Hybrid transgenic mouse with accelerated onsent of Alzheimer type amyloid plaques in brain
AU2003216370A1 (en) *	2002-02-27	2003-09-09	Merck And Co., Inc.	Assays to monitor amyloid precursor protein processing
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
WO2004058686A1 (en) *	2002-04-30	2004-07-15	Elan Pharmaceuticals, Inc.	Hydroxypropyl amides for the treatment of alzheimer’s disease
UY27967A1 (es) *	2002-09-10	2004-05-31	Pfizer	Acetil 2-hindroxi-1,3-diaminoalcanos
CA2507484A1 (en) *	2002-11-27	2004-06-17	Elan Pharmaceuticals, Inc.	Substituted ureas and carbamates
NZ567324A (en)	2003-02-01	2009-08-28	Wyeth Corp	Active immunization to generate antibodies to soluble A-beta
TW200512195A (en) *	2003-04-21	2005-04-01	Elan Pharm Inc	Benzamide 2-hydroxy-3-diaminoalkanes
WO2004094413A1 (en) *	2003-04-21	2004-11-04	Elan Pharmaceuticals, Inc.	Phenacyl 2-hydroxy-3-diaminoalkanes
TWI306458B (en)	2003-05-30	2009-02-21	Elan Pharma Int Ltd	Humanized antibodies that recognize beta amyloid peptide
US20050009110A1 (en) *	2003-07-08	2005-01-13	Xiao-Jia Chang	Methods of producing antibodies for diagnostics and therapeutics
WO2005010039A1 (en) *	2003-07-31	2005-02-03	Pfizer Products Inc.	Bsep polypeptide variants and uses thereof
WO2005070407A1 (en) *	2004-01-21	2005-08-04	Elan Pharmaceuticals, Inc.	Methods of treatment of amyloidosis using aspartyl-protease inihibitors
WO2005087714A2 (en) *	2004-03-09	2005-09-22	Elan Pharmaceuticals, Inc.	Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
JP2007528402A (ja) *	2004-03-09	2007-10-11	エランファーマシューティカルズ，インコーポレイテッド	置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
JP2007528404A (ja)	2004-03-09	2007-10-11	エランファーマシューティカルズ，インコーポレイテッド	置換された尿素およびカルバメート、フェナシル−２−ヒドロキシ−３−ジアミノアルカン、ならびにベンズアミド−２−ヒドロキシ−３−ジアミノアルカン系のアスパラギン酸プロテアーゼ阻害薬
JP2007528400A (ja) *	2004-03-09	2007-10-11	エランファーマシューティカルズ，インコーポレイテッド	置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
US7544855B2 (en) *	2004-04-23	2009-06-09	Buck Institute	Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
WO2005110422A2 (en) *	2004-05-19	2005-11-24	Boehringer Ingelheim International Gmbh	Treatment of diseases associated with altered level of amyloid beta peptides
WO2006010095A2 (en) *	2004-07-09	2006-01-26	Elan Pharmaceuticals Inc.	Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
US20060128715A1 (en) *	2004-07-09	2006-06-15	Jennifer Sealy	Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
US8383637B2 (en) *	2004-08-06	2013-02-26	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8426429B2 (en) *	2004-08-06	2013-04-23	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8436006B2 (en) *	2004-08-06	2013-05-07	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
CA2577392A1 (en) *	2004-08-27	2006-03-09	Elan Pharmaceuticals, Inc.	Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
EP1807119A2 (en) *	2004-11-05	2007-07-18	Wyeth a Corporation of the State of Delaware	Pet and magnetic resonance for screening alzheimer's disease therapeutics
US7625560B2 (en)	2004-12-15	2009-12-01	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
EP1838348B1 (en)	2004-12-15	2013-06-26	Janssen Alzheimer Immunotherapy	Humanized amyloid beta antibodies for use in improving cognition
WO2006089095A2 (en)	2005-02-17	2006-08-24	Biogen Idec Ma Inc.	Treating neurological disorders
JP4853892B2 (ja) *	2005-04-13	2012-01-11	独立行政法人国立精神・神経医療研究センター	変異対立遺伝子に対する特異的なＲＮＡｉの評価方法
CA2607697C (en)	2005-05-10	2015-01-06	Biogen Idec Ma Inc.	Treating and evaluating inflammatory disorders
GB0511861D0 (en) *	2005-06-13	2005-07-20	Merck Sharp & Dohme	Proteins
EP1746092A1 (en)	2005-07-22	2007-01-24	Exonhit Therapeutics SA	Compounds and methods for treatment of amyloid-B-peptide related disorders
EP1913017A1 (en) *	2005-08-03	2008-04-23	Boehringer Ingelheim International GmbH	Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
US20100168070A1 (en) *	2005-08-11	2010-07-01	Niklas Heine	Compounds for the treatment of alzheimer's disease
US20100144681A1 (en) *	2005-08-11	2010-06-10	Klaus Fuchs	Compounds for the treatment of alzheimer's disease
US20090042867A1 (en) *	2005-08-11	2009-02-12	Klaus Fuchs	Compounds for the treatment of alzheimer's disease
EP1915339A1 (de) *	2005-08-11	2008-04-30	Boehringer Ingelheim International GmbH	Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
EP1937638A1 (en) *	2005-10-12	2008-07-02	Elan Pharmaceuticals Inc.	Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
WO2007047305A1 (en) *	2005-10-12	2007-04-26	Elan Pharmaceuticals, Inc.	Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
US7932261B2 (en) *	2006-02-06	2011-04-26	Janssen Pharmaceutica Nv	Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
US7868022B2 (en)	2006-02-06	2011-01-11	Janssen Pharmaceutica Nv	2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
US7776882B2 (en) *	2006-02-06	2010-08-17	Baxter Ellen W	2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
WO2008042024A2 (en)	2006-06-01	2008-04-10	Elan Pharmaceuticals, Inc.	Neuroactive fragments of app
EP3255141B1 (en)	2006-07-13	2021-12-01	Wyeth LLC	Production of antibodies with improved glycosylation pattern
DK2089417T3 (da)	2006-10-12	2015-03-23	Bhi Ltd Partnership	Fremgangsmåder, forbindelser, sammensætninger og vehikler til afgivelse af 3-amion-1-propansulfonsyre
ES2541546T3 (es)	2006-11-03	2015-07-21	Wyeth Llc	Sustancias que inhiben la glucólisis en cultivo celular
AU2008223133A1 (en)	2007-03-02	2008-09-12	Wyeth	Use of copper and glutamate in cell culture for production of polypeptides
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
US8466118B2 (en) *	2007-04-23	2013-06-18	Saint Louis University	Modulation of blood brain barrier protein expression
EP2977452A3 (en)	2007-05-11	2016-05-25	Thomas Jefferson University	Methods of treatment and prevention of neurodegenerative diseases and disorders
US8222264B2 (en)	2007-07-06	2012-07-17	Boehringer Ingelheim International Gmbh	Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
DK2182983T3 (da)	2007-07-27	2014-07-14	Janssen Alzheimer Immunotherap	Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
WO2009097278A1 (en) *	2008-01-28	2009-08-06	Janssen Pharmaceutica N.V.	6-SUBSTITUTED-THIO-2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
EP2240472B1 (en) *	2008-01-29	2012-11-21	Janssen Pharmaceutica NV	2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace)
WO2009105572A2 (en) *	2008-02-19	2009-08-27	Edunn Biotechonology Inc.	Antisense modulation of amyloid beta protein expression
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
US20110023152A1 (en) *	2008-12-04	2011-01-27	Sigma-Aldrich Co.	Genome editing of cognition related genes in animals
ES2705027T3 (es)	2010-08-19	2019-03-21	Buck Institute For Age Res	Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados
CN104270945B (zh)	2012-03-19	2017-03-29	巴克老龄化研究所	App特异性bace抑制剂(asbi)及其用途
CN104619727B (zh)	2012-06-25	2019-04-05	布里格姆及妇女医院股份有限公司	靶向治疗
CA2899938C (en)	2013-02-12	2021-10-19	Buck Institute For Research On Aging	Hydantoins that modulate bace-mediated app processing
US9937231B2 (en)	2013-03-27	2018-04-10	The General Hospital Corporation	Methods and agents for treating Alzheimer's disease
KR101890978B1 (ko)	2014-06-17	2018-08-24	서울대학교산학협력단	알츠하이머 질환 모델용 형질전환 돼지 및 이의 용도
EP3224381B1 (en)	2014-11-25	2019-09-04	The Brigham and Women's Hospital, Inc.	Method of identifying a person having a predisposition to or afflicted with a cardiometabolic disease
WO2016085876A1 (en)	2014-11-25	2016-06-02	The Broad Institute Inc.	Clonal haematopoiesis
EP3341362B1 (en)	2015-08-27	2023-07-05	Nantneuro, LLC	Compositions for app-selective bace inhibition and uses therfor
EP3455223B1 (en)	2016-05-12	2023-11-08	Buck Institute for Research on Aging	Compounds to promote normal processing of app

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
US4492760A (en) *	1983-04-19	1985-01-08	The Wistar Institute Of Anatomy And Biology	HLA D Typing assay
JPS6147500A (ja) *	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) *	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
GB8422238D0 (en) *	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
JPS61134325A (ja) *	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
US4666829A (en) *	1985-05-15	1987-05-19	University Of California	Polypeptide marker for Alzheimer's disease and its use for diagnosis
JPS62100291A (ja) *	1985-10-28	1987-05-09	Teijin Ltd	遺伝子断片およびプラスミド
DE3689123T2 (de) *	1985-11-01	1994-03-03	Xoma Corp	Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
DE3702789A1 (de)	1987-01-30	1988-08-18	Bayer Ag	Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins
AU3056289A (en) *	1988-01-13	1989-08-11	Mclean Hospital Corporation, The	Genetic constructs containing the alzheimer brain amyloid gene
US5134062A (en) *	1988-03-22	1992-07-28	Cornell Research Foundation, Inc.	Diagnosis of neuronal disorders and screening potential therapeutic agents therefor
DE3907562A1 (de)	1989-03-09	1990-09-13	Bayer Ag	Antisense-oligonukleotide zur inhibierung der transaktivatorzielsequenz (tar) und der synthese des transaktivatorproteins (tat) aus hiv-1 und deren verwendung
WO1990013641A1 (en)	1989-05-10	1990-11-15	Sloan-Kettering Institute For Cancer Research	Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter
US5234814A (en) *	1989-06-01	1993-08-10	Du Pont Merck Pharmaceutical Company	Diagnostic assay for alzheimer's disease
WO1991004753A1 (en)	1989-10-02	1991-04-18	Cetus Corporation	Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5180819A (en)	1989-12-22	1993-01-19	The Trustees Of Columbia University In The City Of New York	Purified myeloblastin, nucleic acid molecule encoding same, and uses thereof
EP0451700A1 (en) *	1990-04-10	1991-10-16	Miles Inc.	Recombinant APP minigenes for expression in transgenic mice as models for Alzheimers's disease
JPH05506990A (ja) *	1990-04-24	1993-10-14	ザリージェンツオブザユニバーシティオブカリフォルニア	プロテアーゼ　ネキシン―２の精製、検出、及び使用方法
ES2217250T3 (es) *	1990-06-15	2004-11-01	Scios Inc.	Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
WO1992000521A1 (en) *	1990-06-29	1992-01-09	Case Western Reserve University	Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
US5200339A (en) *	1990-08-17	1993-04-06	Abraham Carmela R	Proteases causing abnormal degradation of amyloid β-protein precursor
BE1003316A5 (fr) *	1990-11-27	1992-02-25	Will L F & Cie Sa	Anticorps monoclonal utile pour le diagnostic de la maladie d'alzheimer, hybridome secreteur d'un tel anticorps monoclonal et procede pour sa preparation.
ES2236682T5 (es) *	1991-01-21	2011-03-31	Elan Pharmaceuticals, Inc.	Ensayo y modelo para la enfermedad de alzheimer.
AU2765992A (en) *	1991-10-03	1993-05-03	Indiana University Foundation	Method for screening for alzheimer's disease
AU671093B2 (en) *	1992-01-07	1996-08-15	Elan Pharmaceuticals, Inc.	Transgenic animal models for alzheimer's disease
US5604102A (en) *	1992-04-15	1997-02-18	Athena Neurosciences, Inc.	Methods of screening for β-amyloid peptide production inhibitors
US7371129B2 (en)	2005-04-27	2008-05-13	Samtec, Inc.	Elevated height electrical connector

1992
- 1992-01-21 ES ES92903304T patent/ES2236682T5/es not_active Expired - Lifetime
- 1992-01-21 JP JP50357592A patent/JP3510244B2/ja not_active Expired - Lifetime
- 1992-01-21 AT AT99109196T patent/ATE447016T1/de not_active IP Right Cessation
- 1992-01-21 EP EP99109196A patent/EP0971033B1/en not_active Revoked
- 1992-01-21 AT AT92903304T patent/ATE286971T1/de not_active IP Right Cessation
- 1992-01-21 EP EP92903304A patent/EP0568575B2/en not_active Expired - Lifetime
- 1992-01-21 DK DK99109196T patent/DK0971033T3/da active
- 1992-01-21 WO PCT/GB1992/000123 patent/WO1992013069A1/en not_active Ceased
- 1992-01-21 AU AU11694/92A patent/AU652997B2/en not_active Expired
- 1992-01-21 ES ES99109196T patent/ES2335720T3/es not_active Expired - Lifetime
- 1992-01-21 CA CA002372251A patent/CA2372251A1/en not_active Abandoned
- 1992-01-21 DE DE69233774T patent/DE69233774D1/de not_active Expired - Lifetime
- 1992-01-21 DK DK92903304.1T patent/DK0568575T4/da active
- 1992-01-21 CA CA2101774A patent/CA2101774C/en not_active Expired - Lifetime
- 1992-01-21 US US08/104,165 patent/US5877015A/en not_active Expired - Lifetime
- 1992-01-21 DE DE69233468T patent/DE69233468T3/de not_active Expired - Lifetime
- 1992-01-21 DE DE0971033T patent/DE971033T1/de active Pending
1995
- 1995-06-05 US US08/464,250 patent/US6300540B1/en not_active Expired - Lifetime
2001
- 2001-12-27 JP JP2001397308A patent/JP3574432B2/ja not_active Expired - Lifetime
2003
- 2003-02-03 US US10/357,935 patent/US20030165958A1/en not_active Abandoned
2004
- 2004-04-30 JP JP2004136760A patent/JP2004261187A/ja active Pending

Also Published As

Publication number	Publication date
CA2101774C (en)	2011-01-04
DE971033T1 (de)	2001-05-03
ES2236682T5 (es)	2011-03-31
AU652997B2 (en)	1994-09-15
JP3510244B2 (ja)	2004-03-22
ATE447016T1 (de)	2009-11-15
US5877015A (en)	1999-03-02
US6300540B1 (en)	2001-10-09
EP0568575A1 (en)	1993-11-10
WO1992013069A1 (en)	1992-08-06
DK0568575T3 (da)	2005-05-23
JPH06504441A (ja)	1994-05-26
ES2335720T3 (es)	2010-03-31
CA2372251A1 (en)	1992-08-06
JP2002306195A (ja)	2002-10-22
AU1169492A (en)	1992-08-27
EP0971033A2 (en)	2000-01-12
EP0568575B1 (en)	2005-01-12
JP3574432B2 (ja)	2004-10-06
DE69233468T3 (de)	2011-05-05
DE69233468D1 (de)	2005-02-17
ATE286971T1 (de)	2005-01-15
DE69233774D1 (de)	2009-12-10
DE69233468T2 (de)	2005-12-22
EP0568575B2 (en)	2010-11-03
EP0971033A3 (en)	2003-11-12
JP2004261187A (ja)	2004-09-24
ES2236682T3 (es)	2005-07-16
CA2101774A1 (en)	1992-07-22
DK0971033T3 (da)	2009-12-14
US20030165958A1 (en)	2003-09-04
EP0971033B1 (en)	2009-10-28

Publication	Publication Date	Title
DK0568575T3 (da)	2005-05-23	Test og model for Alzheimers sygdom
DE69839808D1 (de)	2008-09-11	Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung
NO308029B1 (no)	2000-07-10	Inhibitorer av <beta>-amyloidproteinproduksjon og farmasøytisk preparat inneholdende disse
EP0670731A4 (en)	1997-06-11	TREATMENT OF AMNESIA DUE TO THE DEPOSITION OF THE AMYLOID PROTEIN -g (b) IN ALZHEIMER'S DISEASE.
ES2120401T3 (es)	1998-11-01	Proteina recombinante amiloide relacionados con la enfermedad de alzheimer.
FI951701A0 (fi)	1995-04-10	Menetelmät Alzheimerin taudin tunnistamiseksi
DK0618968T3 (da)	2000-04-10	Midler til diagnostisering og behandling af Alzheimer's sygdom
ATE239797T1 (de)	2003-05-15	Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
BR9712077A (pt)	2003-04-29	Expressão de proteìnas de alto nìvel
DK150992A (da)	1992-12-17	Fremgangsmaade til fremstilling af et polypeptidfragment af faktor viii:c, dna-sekvens og ekstrachromosomalt element indeholdende en saadan dna-sekvens, som koder herfor
NO20011891L (no)	2001-07-02	Anvendelse av radioligander for screening av inhibitorer av amyloid-<beta>-peptid produksjon
DE69535274D1 (de)	2006-11-30	Verwendung eines menschlichen interleukin-11 rezeptors
DK0948604T3 (da)	2004-11-22	Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
DK1330656T3 (da)	2008-08-11	Midler til detektion af patologiske transformationer af proteinet APP og anvendelser heraf
ATE417930T1 (de)	2009-01-15	Proteinkinase npk-110
EP0716591A4 (en)	1998-02-04	METHODS AND COMPOSITIONS FOR BINDING TAU AND MAP2c PROTEINS
FI822065A7 (fi)	1982-12-24	Menetelmä aspartiinihapon ja glutamiinihapon täydelliseksi tai osittaiseksi poistamiseksi proteiiniproteiinihydrolyysisaasteista ja aminohapposeoksista sekä näin saadut aminohapposeokset.
Benuck et al.	1996	Changes in brain protease activity in aging
DK1373502T3 (da)	2011-01-10	Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf
FI904087A7 (fi)	1990-08-17	Monoklonaalisia vasta-aineita aktivoituja ras-proteiineja vastaan, joi lla on aminohappomutaatioita proteiinin kohdassa 13
DE3856364D1 (de)	1999-11-04	Verarbeitungssystem zur Fehlerinformationssammlung
MX9304839A (es)	1994-02-28	Marcador para determinar la inclusion de un bovino en un programa de cria.
ATE315582T1 (de)	2006-02-15	Verwendung von neuregulin-beta als indikator und/oder target
DE69734890D1 (de)	2006-01-19	Rdgb-proteine
DK0972781T3 (da)	2007-03-05	Protein S-polypeptider og anvendelser deraf